ICU Medical (STU:IC7) ROCE %: 4.80% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IC7 ICU Medical Inc STU:IC7
80 GF Score
Price €158.00
GF Value €105.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is ICU Medical ROCE %?

ICU Medical STU:IC7 80 ROCE % is 4.80% as of Jun. 2026. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ICU Medical's annualized ROCE % for the quarter that ended in Jun. 2026 was 4.80%.

ICU Medical  (STU:IC7) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ICU Medical ROCE % Related Terms

ICU Medical ROCE % Historical Data

* Premium members only.

The historical data trend for ICU Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ICU Medical ROCE % Chart

ICU Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.91 -1.56 0.61 1.10 2.56

ICU Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.05 2.16 0.77 1.66 4.80
STU:IC7
80GF Score
ICU Medical Inc STU:IC7
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ICU Medical ROCE % Calculation

ICU Medical's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=83.432/( ( (4014.754 - 531.154) + (3459.134 - 426.027) )/ 2 )
=83.432/( (3483.6+3033.107)/ 2 )
=83.432/3258.3535
=2.56 %

ICU Medical's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=144.784/( ( (3471.905 - 447.987) + (3447.073 - 432.58) )/ 2 )
=144.784/( ( 3023.918 + 3014.493 )/ 2 )
=144.784/3019.2055
=4.80 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 4.80% mean?
ICU Medical (STU:IC7) has a ROCE % of 4.80% as of Jun. 2026.
Is ICU Medical's ROCE % too high?
ICU Medical's current ROCE % is 4.80%. The Medical Devices & Instruments industry median ROCE % is 2.93. ICU Medical's value of 4.80% is 63.8% above this industry median. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's ROCE % compare to NVST and MMSI?
ICU Medical's ROCE % of 4.80% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.93. ICU Medical's value of 4.80% is 63.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.93, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current ROCE % of 4.80% is 63.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current ROCE % is 4.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current ROCE % is 4.80% and 63.8% above the Medical Devices & Instruments industry median of 2.93. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current ROCE % is 4.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ICU Medical (STU:IC7) Overvalued in 2026?

Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued. The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79. GuruFocus considers ICU Medical to be Significantly Overvalued.

Key valuation signals for STU:IC7:

  • ROCE %: 4.80%
  • GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
  • GF Score™: 80/100 with 8 warning signs
  • Industry Position: 63.8% above the Medical Devices & Instruments median

No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ICU Medical Business Description

Other Exchanges ICUI:USA
Address 951 Calle Amanecer, San Clemente, CA, USA, 92673
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score

Get the complete analysis for STU:IC7

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€158.00
Price
€105.79
GF Value